# Arboviral Encephalitis

Arboviral encephalitis requires early syndromic stabilization, empiric acyclovir while treatable causes are evaluated, and epidemiologically targeted serology coordinated with public health laboratories. Interpretation is complicated by flavivirus antibody cross-reactivity and impaired humoral responses in B-cell-depleted patients.

**Clinical question:** How should physicians evaluate, confirm, and manage suspected arboviral encephalitis in the United States?

Updated: 2026-08-21T01:22:06.156634+00:00

## What matters in practice
- Treat suspected encephalitis as an acute neurologic emergency: initiate empiric acyclovir while diagnostic studies are pending, because herpes simplex encephalitis remains a treatable competing diagnosis. [9]
- Select arboviral testing by illness timing, immune status, vaccination and travel history, local circulation, and the regional differential; similar CNS syndromes are produced by many infectious and noninfectious disorders. [12]
- Positive flavivirus IgM or IgG screening results are not species-specific; confirmatory plaque-reduction neutralization testing is recommended to distinguish cross-reactive flavivirus infections. [12]
- Patients receiving rituximab or related B-cell-depleting therapies are at particularly high risk for severe arboviral neuroinvasive disease and may have atypical diagnostic challenges. [14][20]
- There is no established virus-directed therapy in the supplied evidence; management of arboviral encephalitis is supportive, with ICU-level organ and neurologic support when indicated. [2][5][6]

## When to suspect arboviral encephalitis

Use epidemiology to prioritize testing, not to exclude competing treatable causes.

Arboviruses can produce a spectrum from clinically inapparent infection or nonspecific febrile illness to meningitis, encephalitis, and death. Neuroinvasive disease should enter the differential for acute febrile neurologic illness during vector season, after relevant mosquito or tick exposure, in an area with known circulation, or after travel to an endemic region. [12][17]

In the United States, West Nile virus is the most commonly diagnosed arboviral disease and a leading consideration in seasonal neuroinvasive illness; however, regional alternatives matter. California serogroup viruses, including La Crosse virus, are important causes of pediatric arboviral encephalitis, particularly in Midwest and Appalachian regions. [18][19]

Do not anchor on arbovirus. The differential for arboviral CNS disease includes other viral, bacterial, mycoplasmal, protozoal, fungal, toxic, metabolic, and postinfectious conditions. Parallel evaluation for alternative, potentially treatable etiologies is necessary. [12]
- Increase suspicion in patients with fever followed by confusion, tremor, focal neurologic deficits, ascending paralysis, progressive cognitive decline, unresponsiveness, or coma, especially when immunocompromised. [14]
- Ask specifically about onset location, travel, outdoor and vector exposure, season, vaccination history, and local public-health alerts; these variables inform test selection and interpretation. [12][17]
- Consider unusual or imported arboviruses in international travelers and report suspected unusual arboviral etiologies promptly to local or state public health authorities. [17]

*Epidemiologic features that should redirect arboviral testing strategy. [12][17][18]*

| Clinical context | Testing implication |
| --- | --- |
| Acute neurologic syndrome during local mosquito or tick season | Order testing for arboviruses active or present in the relevant geographic region rather than West Nile virus testing alone. [12] |
| Child with encephalitis in Midwest or Appalachian region | Include California serogroup viruses, particularly La Crosse virus, in the diagnostic differential. [18] |
| International travel or unusual exposure history | Broaden beyond endemic U.S. agents and notify public health authorities when exotic arboviral infection is suspected. [17] |
| Rituximab or related B-cell depletion | Maintain heightened concern for severe neuroinvasive disease and coordinate early with infectious diseases, neurology, and public health laboratory services. [14][20] |

## Stabilize first and cover treatable encephalitis

Arboviral confirmation should not delay emergency encephalitis care.

Patients can deteriorate rapidly from impaired consciousness, seizures, autonomic dysfunction, cerebral edema, or respiratory failure. ICU admission is appropriate when airway protection, ventilatory support, circulatory support, or close neurologic monitoring is required. [2][5][7]

Start acyclovir in all patients with suspected encephalitis while diagnostic studies are pending. This recommendation is directed at empiric coverage of herpes simplex virus and should not be interpreted as evidence of activity against arboviruses. [9]

Once arboviral encephalitis is the working diagnosis, treatment is supportive. The supplied evidence does not establish a specific antiviral, immunotherapy, or corticosteroid regimen that improves arboviral encephalitis outcomes. [2][6][18]
- Protect the airway when altered consciousness compromises airway reflexes; provide ventilatory and hemodynamic support as clinically indicated. [2][5][7]
- Monitor for and treat seizures; manage suspected intracranial hypertension or cerebral edema using critical-care and neurocritical-care principles, recognizing that efficacy of reported adjunctive therapies in encephalitis is unproven in the supplied evidence. [7]
- Continue surveillance for secondary complications including pneumonia, venous thromboembolism, dysnatremias, arrhythmias, and hypotension in severe disease. [7]
- Avoid premature discontinuation of empiric therapy for other treatable CNS infections until the diagnostic evaluation and clinical course justify de-escalation. [9][12]

*Immediate management priorities in suspected arboviral encephalitis. [2][5][7][9]*

| Priority | Action | Clinical rationale |
| --- | --- | --- |
| Airway and ventilation | Escalate to ICU-level monitoring and intubate when airway protection is compromised. [2][5][7] | Encephalitis may cause rapid neurologic decline and respiratory failure. [2][5] |
| Treatable viral encephalitis coverage | Initiate empiric acyclovir pending diagnostic results. [9] | HSV encephalitis is a time-sensitive alternative diagnosis; this does not treat arboviral infection. [9] |
| Neurologic complications | Monitor for seizures, cerebral edema, autonomic instability, and dysnatremias; intervene according to critical-care assessment. [7] | These complications contribute materially to morbidity in severe encephalitis. [7] |
| Supportive care | Provide organ support and prevent complications of critical illness. [2][5][7] | Supportive care is the mainstay for arboviral encephalitis. [2][6] |

## Order epidemiologically targeted testing and interpret serology cautiously

Laboratory confirmation depends on agent-specific assays and context.

Definitive arboviral diagnosis requires laboratory testing with specific reagents. Test selection should account for age, immune status, vaccination history, timing of infection, pathogens in the differential, and the capabilities of initial and confirmatory laboratories. [12]

Send serum and CSF as appropriate for arboviral testing and involve the hospital laboratory, state health department, or public health laboratory early when a neuroinvasive arboviral syndrome is suspected. Specimens submitted for West Nile virus testing should also be assessed for other arboviruses known to be active or present in the relevant area or travel region. [12]

Flavivirus serology has a major interpretive limitation: IgM and IgG assays may cross-react among West Nile, St. Louis encephalitis, dengue, yellow fever, Powassan, and other flaviviruses. Treat initial flavivirus antibody results as screening results and pursue plaque-reduction neutralization testing for species differentiation when confirmation is clinically or epidemiologically important. [12]

B-cell depletion changes both risk and diagnostic reasoning. CDC describes severe neuroinvasive arboviral disease among patients receiving rituximab and related agents, with a reported case-series mortality of 4 of 5 patients diagnosed with arboviral neuroinvasive disease; survivors often had long-term cognitive or motor disability. A negative or delayed antibody response may be a concern in this population, warranting early specialist and public-health laboratory coordination. [14][20]
- Order testing based on the patient's exposure geography and season, not solely on the most common local agent. [12][17]
- Interpret a positive flavivirus screening antibody test alongside prior flavivirus infection, vaccination, travel, and regional circulation; request confirmatory neutralization testing when cross-reactivity is plausible. [12]
- Document immune-modifying therapy, especially anti-CD20 therapy, on laboratory requisitions and in consultations because it materially alters pretest probability and may complicate serologic interpretation. [14]

### Neuroimaging

MRI is generally more informative than CT in encephalitis evaluations. In one large encephalitis study, MRI abnormalities were particularly frequent with herpes simplex virus and acute disseminated encephalomyelitis, underscoring that imaging contributes to the broader differential rather than establishing arboviral etiology. [1]
- Reported Eastern equine encephalitis MRI abnormalities often involve basal ganglia, thalami, and brainstem, but this pattern is not sufficient for diagnosis without compatible epidemiology and laboratory confirmation. [24]

*Practical interpretation of arboviral laboratory testing. [12][14]*

| Result or circumstance | Interpretation | Next action |
| --- | --- | --- |
| Positive flavivirus IgM or IgG screening assay | Possible recent or prior flavivirus exposure, but cross-reactivity limits species attribution. [12] | Request confirmatory plaque-reduction neutralization testing when clinically or epidemiologically necessary. [12] |
| West Nile virus testing requested in a patient with compatible syndrome | West Nile virus is common, but other regional arboviruses may produce indistinguishable presentations. [12][19] | Ensure testing includes other arboviruses active or present in the exposure region. [12] |
| Negative or nondiagnostic serology in B-cell-depleted patient | Humoral testing may be difficult to interpret in a host at high risk for severe disease. [14] | Consult infectious diseases and public health laboratory services early for case-specific diagnostic planning. [14] |
| Suspected imported or unusual arbovirus | Potential public-health risk, particularly where competent vectors exist. [17] | Report promptly to local or state public health agencies and coordinate specialized testing. [17] |

## Report promptly and use diagnosis to guide prevention

Clinical confirmation has individual and population-level value.

Timely diagnosis and reporting can clarify exposure source, prevent unnecessary antimicrobial treatment, and allow public health authorities to detect and respond to additional cases. [14]

Counsel patients, particularly those who are immunocompromised, on seasonal and geographic risk and on personal measures to prevent mosquito and tick bites. [14] There is no routine human vaccine strategy for the major endemic U.S. arboviral encephalitides described in the supplied sources; prevention therefore relies primarily on vector-exposure reduction and public-health surveillance.
- Notify local or state public health authorities for suspected arboviral disease, particularly neuroinvasive, unusual, travel-associated, or clustered cases. [14][17]
- For positive flavivirus screening results, coordinate confirmatory testing through appropriate public health channels because species-level attribution may affect surveillance and response. [12]
- Provide targeted prevention counseling to patients receiving B-cell-depleting therapy because severe neuroinvasive outcomes have been reported in this group. [14][20]

*Reporting and prevention actions with clinical value. [12][14][17]*

| Situation | Physician action |
| --- | --- |
| Suspected arboviral neuroinvasive disease | Report to local or state public health authorities and coordinate agent-specific testing. [14][17] |
| Flavivirus screening-seropositive specimen | Arrange confirmatory plaque-reduction neutralization testing when differentiation is needed. [12] |
| Immunocompromised patient at seasonal risk | Discuss mosquito and tick bite prevention and maintain a lower threshold for evaluation of febrile neurologic illness. [14] |

## Common questions

### Should empiric acyclovir be given when arboviral encephalitis is suspected?

Yes. Acyclovir should be started in all patients with suspected encephalitis while diagnostic studies are pending because a treatable herpes simplex virus encephalitis remains in the differential. It is not established therapy for arboviral infection. [9]

### How should a positive West Nile or other flavivirus IgM test be interpreted?

Interpret it as a screening result rather than definitive species identification. Flavivirus IgM and IgG tests can cross-react, so plaque-reduction neutralization testing is recommended when differentiation among flaviviruses is required. [12]

### When should physicians test beyond West Nile virus?

Test for other arboviruses active or present in the patient's exposure region or travel destination, because multiple arboviruses produce overlapping meningitis and encephalitis syndromes. [12][17]

### Why is rituximab exposure important in suspected arboviral encephalitis?

B-cell depletion is associated with severe arboviral neuroinvasive disease. CDC reports high mortality and long-term neurologic disability in a rituximab-associated case series, supporting heightened suspicion and early specialist and public-health laboratory involvement. [14][20]

## References
1. Causes of encephalitis and differences in their clinical ... — www.thelancet.com — https://www.thelancet.com/article/S1473-3099(10)70222-X/fulltext
2. Eastern Equine Encephalitis Virus — Another Emergent ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMp1914328
3. Flavivirus Encephalitis — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMra030476
4. Viral Encephalitis — www.nejm.org — https://www.nejm.org/doi/pdf/10.1056/NEJM199007263230406
5. Intensive care management of patients with viral encephalitis — www.sciencedirect.com — https://www.sciencedirect.com/science/article/am/pii/S0035378721007864
6. La Crosse Encephalitis - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/neuroscience/la-crosse-encephalitis
7. Allergic Encephalitis - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/allergic-encephalitis
8. Predominance of arboviruses in acute encephalitis and ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1201971226002997
9. Management of Encephalitis: Clinical Practice Guidelines by ... — academic.oup.com — https://academic.oup.com/cid/article/47/3/303/313455
10. Epidemic/Epizootic West Nile Virus in the United States — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/7271/cdc_7271_DS1.pdf
11. SURVEILLANCE GUIDE FOR REPORTING ARBOVIRAL ... — ndc.services.cdc.gov — https://ndc.services.cdc.gov/wp-content/uploads/ArboviralDiseaseReportingSurveillanceGuide_December-2021_12-10-21.pdf
12. Guidelines for West Nile Virus Surveillance and Control | West Nile Virus | CDC — www.cdc.gov — https://www.cdc.gov/west-nile-virus/php/surveillance-and-control-guidelines/index.html
13. WHO guidelines for clinical management of arboviral diseases: — iris.who.int — https://iris.who.int/server/api/core/bitstreams/634a55a5-327e-459b-a633-0650fe8ad6c9/content
14. Clinical Guidance for Vector-Borne Viral Diseases in People Who Are Immunocompromised | Vector-Borne Diseases | CDC — www.cdc.gov — https://www.cdc.gov/vector-borne-diseases/hcp/clinical-guidance-immunocompromised/index.html
15. Guidelines for Eastern Equine Encephalitis Virus ... — www.cdc.gov — https://www.cdc.gov/eastern-equine-encephalitis/php/surveillance-and-control-guidelines/index.html
16. Arboviral Infections of the Central Nervous System — www.cdc.gov — https://www.cdc.gov/mmwr/PDF/wk/mm4725.pdf
17. Arboviral Diseases, Neuroinvasive and Non-neuroinvasive 2014 Case Definition | CDC — ndc.services.cdc.gov — https://ndc.services.cdc.gov/case-definitions/arboviral-diseases-neuroinvasive-and-non-neuroinvasive-2014
18. Neutralizing Antibodies against California Serogroup Orthobunyaviruses in Human Serum Samples, Montana, USA - Volume 31, Number 4—April 2025 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/31/4/24-1520_article
19. Use of Testing for West Nile Virus and Other Arboviruses - Volume 22, Number 9—September 2016 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/22/9/15-2050_article
20. Severe Arboviral Neuroinvasive Disease in Patients on Rituximab Therapy: A Review — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/125735
21. evaluation for arboviral infection among children ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/121852/cdc_121852_DS1.pdf
22. Severe Arboviral Neuroinvasive Disease in Patients on ... — stacks.cdc.gov — https://stacks.cdc.gov/view/cdc/125735/cdc_125735_DS1.pdf
23. Arbovirus Epidemics as Global Health Imperative, Africa, 2023 - Volume 31, Number 2—February 2025 - Emerging Infectious Diseases journal - CDC — wwwnc.cdc.gov — https://wwwnc.cdc.gov/eid/article/31/2/24-0754_article
24. Successful Treatment of Eastern Equine Encephalitis with ... — www.neurology.org — https://www.neurology.org/doi/10.1212/WNL.84.14_supplement.P6.306

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.